HomeTagsHighTide Therapeutics Inc.

Tag: HighTide Therapeutics Inc.

spot_imgspot_img
Medical

HighTide Therapeutics Presents Analyses of Phase 2a MASH Study at the 2024 International Liver Congress, Reinforcing and Further Characterizing the Efficacy and Safety of...

HighTide Therapeutics, Inc. (HKG: 2511), a clinical stage biopharmaceutical company specializing in the development of multi-targeted therapies for chronic liver and metabolic diseases, announced...
Medical

HighTide Therapeutics Announces First Patient Dosed in Phase 2b Clinical Study Evaluating HTD1801 in NASH (the CENTRICITY study)

HighTide Therapeutics Inc. (HighTide), a globally integrated clinical-stage biopharmaceutical company developing novel multifunctional therapies for metabolic and digestive diseases, today announced the dosing of...
Medical

HighTide Therapeutics Raises $107 Million in Series C/C+ Financing to Advance Innovative Pipeline and Business Collaborations

Global biopharmaceutical company focusing on metabolic and digestive diseases Proceeds to fund clinical and business development HighTide Therapeutics Inc. (HighTide), a globally integrated clinical-stage...
12Page 2 of 2

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from up to 5 devices at once

Must read

spot_img